Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04110977
Other study ID # RAREST-02
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 10, 2020
Est. completion date November 2021

Study information

Verified date November 2020
Source University Hospital Schleswig-Holstein
Contact Dirk Rades, Professor
Phone +49 451 500
Email dirk.rades@uksh.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomized trial is to investigate whether the addition of a reminder app to standard care leads to a reduction of dermatitis and oral mucositis during radio(chemo)therapy for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN). The primary endpoint is the rate of patients experiencing grade ≥2 radiation dermatitis at 60 Gy of radiotherapy. 80 patients are required per arm within the full analysis set. Taking into account that 5% of patients will not qualify for full analysis set, 168 patients should be randomized. If the addition of a reminder app to standard care will result in a significant reduction of radiation toxicity, it could become a helpful tool for these patients.


Description:

The goal of this trial is to investigate whether the addition of a reminder app to standard care leads to a reduction of dermatitis and oral mucositis during radio(chemo)therapy for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN). This is a randomized, active-controlled, parallel-group trial, which will compare the following treatments of radiation dermatitis (primary endpoint) and oral mucositis in patients with SCCHN: Standard care supported by a reminder app (Arm A) vs. standard care alone (Arm B). The primary endpoint is to investigate the rate of patients experiencing grade ≥2 radiation dermatitis at 60 Gy of radiotherapy, the minimum planned total dose for all patients receiving definitive or adjuvant radiotherapy for locally advanced SCCHN with curative intention. In addition, the following endpoints will be evaluated: Radiation dermatitis grade ≥2 at the end of radiation treatment (EOT), radiation dermatitis grade ≥3 at 60 Gy and EOT, quality of life, pain, and radiation-induced oral mucositis grade ≥2 and grade ≥3 at 60 Gy and at EOT. According to sample size calculations, 80 patients are required per arm within the full analysis set. Taking into account that 5% of patients will not qualify for full analysis set, 168 patients should be randomized. The impact of the reminder app will be considered clinically relevant, if the rate of grade ≥2 radiation dermatitis can be reduced from 85% to 65%. If the addition of a reminder app to standard care will result in a significant reduction of radiation dermatitis and oral mucositis, it could become a helpful tool for patients during radiotherapy of for SCCHN.


Recruitment information / eligibility

Status Recruiting
Enrollment 168
Est. completion date November 2021
Est. primary completion date November 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically proven squamous cell carcinoma of the head-and-neck (SCCHN) - Indication for definitive or adjuvant radio(chemo)therapy - Possession of and ability to use a smart phone - Age =18 years - Written informed consent - Capacity of the patient to contract Exclusion Criteria: - Nasopharynx cancer - Pregnancy, Lactation - Treatment with epidermal growth factor receptor (EGFR)-antibodies (either given or planned) - Expected non-compliance

Study Design


Intervention

Device:
mobile application (reminder app)
This app will remind the patients four times a day to perform skin and mouth care. Instructions are given how to properly perform skin and mouth care. The patients may postpone each required care procedure for up to 2 hours. Finally, the patients are asked to state for each procedure whether or not they performed it. To increase the patients' motivation, they will earn points for each successfully performed care procedure.

Locations

Country Name City State
Germany Medical Practice for Radiotherapy and Radiation Oncology Hannover Niedersachsen
Germany Dept. of Radiation Oncology, University of Lübeck Lübeck Schleswig-Holstein
Spain Department of Radiation Oncology, Cruces University Hospital/ Biocruces Health Research Institute Barakaldo Vizcaya
Spain Dept. of Radiation Oncology, Hospital Universitario y Politecnico La Fe, Valencia

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Schleswig-Holstein

Countries where clinical trial is conducted

Germany,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of radiation dermatitis grade =2 at least moderate radiation-induced skin toxicity such as erythema and desquamation until 60 Gy of radiotherapy
Secondary Rate of radiation dermatitis grade =2 at least moderate radiation-induced skin toxicity such as erythema and desquamation at the end of radiotherapy
Secondary Rate of radiation dermatitis grade =3 severe radiation-induced skin toxicity such as erythema and desquamation at 60 Gy of radiotherapy and at the end of radiotherapy
Secondary Pain score Pain within the radiation fields measured with a self-rating analogue scale ranging from 0 (no pain) to 10 (maximum pain) points; higher values represent worse outcomes. prior to radiotherapy, weekly during radiotherapy, at 60 Gy and at the end of radiotherapy
Secondary Rate of radiation-induced oral mucositis grade =2 at least moderate radiation-induced inflammation of the oral mucosa at 60 Gy of radiotherapy and at the end of radiotherapy
Secondary Rate of radiation-induced oral mucositis grade =3 severe radiation-induced inflammation of the oral mucosa at 60 Gy of radiotherapy and at the end of radiotherapy
See also
  Status Clinical Trial Phase
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Not yet recruiting NCT06040983 - Clinical Investigation on the Treatment of Radiation Induced Dermatitis With FR-101 Chest Dressing N/A
Withdrawn NCT05505214 - Topical Steroids & Bacterial Decolonization for Radiation Dermatitis Phase 2
Withdrawn NCT04593914 - A Novel Skin Barrier Protectant for Acute Radiodermatitis N/A
Completed NCT05450848 - StrataXRT vs. Standard Clinical Practice in the Prevention and Treatment of Radiation Dermatitis N/A
Active, not recruiting NCT05594498 - A Study of StrataXRT in the Prevention of Radiation Dermatitis in Breast Cancer Patients N/A
Recruiting NCT06158347 - Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation Dermatitis in Patients With Localized Breast Cancer N/A
Recruiting NCT05553392 - StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis N/A
Active, not recruiting NCT04268056 - Characterization of Skin Microbiome Profile and it's Correlation to Radiation Dermatitis
Not yet recruiting NCT04888234 - Evaluation the Effectiveness of Ru-Yi-Jin-Huang Powder for the Radiation-induced Dermatitis. Phase 2
Terminated NCT01597921 - A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer N/A
Completed NCT00481884 - Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients Phase 3
Completed NCT03494205 - Urtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis Phase 2
Completed NCT05810194 - Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis
Completed NCT03941665 - Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients N/A
Not yet recruiting NCT02051907 - Clinical Study to Evaluate Safety and Efficacy of KAM1403 Gel to Treat Radiation Dermatitis Phase 2
Completed NCT02839473 - Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial Phase 3
Completed NCT00573365 - LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis N/A
Completed NCT00876642 - Trial Comparing Best Supportive Care to Aloe Vera Gel Phase 3
Completed NCT03910595 - Efficacy Study of Mepitel Film the Prophylaxis of Radiation-Induced Skin Reactions in Breast Cancer Patients N/A